How Can India Ensure Timely Access to Lenacapavir for Global HIV Challenges?
Click to start listening
Synopsis
India is at a pivotal moment in the fight against HIV. With lenacapavir, the WHO-recommended injectable PrEP, the country can lead the charge in ensuring equitable access. Experts stress the need for timely distribution to address global HIV challenges effectively.
Key Takeaways
- Lenacapavir offers a new, effective alternative to daily PrEP.
- Only two doses are needed per year, simplifying adherence.
- Generic versions will significantly reduce costs for patients.
- India has the potential to lead in the global distribution of lenacapavir.
- Public health collaborations are crucial for successful rollout.
New Delhi, Sep 29 (NationPress) It is essential for India to guarantee fair and prompt global access to lenacapavir, the World Health Organization (WHO) endorsed product that is the first injectable pre-exposure prophylaxis (PrEP) administered twice yearly, to address the global HIV crisis, according to an expert's statement on Monday.
The lenacapavir injection serves as an additional PrEP option, providing a highly effective and long-lasting alternative to daily oral medications and other shorter-acting treatments.
With only two doses required annually, lenacapavir marks a revolutionary advancement in safeguarding individuals at risk of HIV, especially those who encounter difficulties with daily compliance, stigma, or healthcare accessibility.
“India must take the lead in guaranteeing fair and prompt global access to lenacapavir,” emphasized Dr. Ishwar Gilada, President Emeritus of the AIDS Society of India (ASI).
“Only India, with its established history, is capable of delivering this with the necessary quality, scale, and speed,” he added.
Branded as Yeztugo, lenacapavir, developed by the global pharmaceutical leader Gilead Sciences, is priced at $28,218 per individual annually.
Recently, Indian pharmaceutical companies Dr Reddy's Laboratories and Hetero Labs have announced they will provide generic versions of lenacapavir for approximately $40 per year starting in 2027.
While Hetero has collaborated with the Gates Foundation, Dr. Reddy’s Laboratories (DRL) is backed by Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI to offer technical and financial aid in the development of the generic variant.
“This is a significant milestone for public health—making a generic version of lenacapavir affordable for everyone who needs it. It showcases how a groundbreaking scientific advancement by Gilead, presenting a hopeful substitute to daily oral PrEP, can truly make an impact when paired with a vital contribution from Indian pharmaceutical companies focused on access and affordability, ” stated Gilada, Secretary General of the People’s Health Organisation (PHO).
The expert also called upon the National AIDS Control Organisation (NACO) of India to prioritize the rollout of the domestically produced generic lenacapavir within India first.
Point of View
I believe it is imperative that India takes the reins in ensuring that lenacapavir is accessible to all who need it. With the country’s robust pharmaceutical sector and commitment to public health, we have the opportunity to demonstrate leadership in the global fight against HIV.
NationPress
29/09/2025
Frequently Asked Questions
What is lenacapavir?
Lenacapavir is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) recommended by the WHO, designed to significantly reduce the risk of HIV transmission.
How does lenacapavir differ from traditional PrEP?
Unlike daily oral PrEP, lenacapavir requires only two doses per year, making it a more practical option for individuals facing challenges with daily adherence.
What are the costs associated with lenacapavir?
The branded version of lenacapavir costs approximately $28,218 per person per year, while generic versions are expected to be available for around $40 annually starting in 2027.
How can India ensure equitable access to lenacapavir?
India can lead by collaborating with its pharmaceutical industry to produce generics and implementing effective distribution strategies to reach those in need.
Why is lenacapavir significant for public health?
Lenacapavir represents a groundbreaking innovation that could transform HIV prevention and improve accessibility for high-risk populations.
